INFECTION PROPHYLAXIS IN NEUTROPENIC PATIENTS WITH ACUTE-LEUKEMIA - A RANDOMIZED, COMPARATIVE-STUDY WITH OFLOXACIN, CIPROFLOXACIN AND COTRIMOXAZOLE COLISTIN

Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia. The results for 59 patients (median age 47 years, range 21–72) included 88 episodes of neutropenia, each associated with a course of cytotoxic therapy. The main factor measured was the time elapsed from the beginning of neutropenia (neutrophils < 500/µl) until the first infectious febrile episode. The median time for the period was 12 days (range 1–56) for the cotrimoxazole/colistin group, 15 days (range 1–38) for the ofloxacin group and 20 days (range 1–36) for the ciprofloxacin group (differences not significant). Microbiologically proven major infections occurred in 10/27 treatment courses with cc-trimoxazole/colistin, 7/31 courses with ofloxacin and 7/30 courses with ciprofloxacin (P not significant). These were mostly due to Gram-positive cocci. There were no Gramnegative infections in the quinolone groups compared with one major Pseudomonas aeruginosa infection in the co-trimoxazole/colistin group. No Pnewnocystis carinii infections were encountered. Adverse reactions associated with co-trimoxazole/colistin required discontinuation of medication in 11/27 treatment courses because of compliance problems, skin reactions or gastrointestinal intolerance. There were significantly fewer discontinuations in the ofloxacin (n = 2) and in the ciprofloxacin groups (n = 3). Major side effects of the quinolones included persistent icterus in one patient receiving ofloxacin and psychiatric symptoms in one patient receiving ciprofloxacin. It is concluded from these data that there were no statistically significant differences between the three treatment groups in respect of the prevention of infection. However, both quinolones were better tolerated and accepted by the patients than co-trimoxazole/colistin. © 1990 The British Society for Antimicrobial Chemotherapy.